Teprotumumab: a disease modifying treatment for graves’ orbitopathy

BACKGROUND: On 21st January 2020, the FDA approved Tepezza (teprotumumab-trbw) for the treatment of active Graves’ orbitopathy (GO) in adults. This approval was based on positive results from two multinational randomised double-blind placebo-controlled clinical trials. DISCUSSION: This article discu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ting, Michelle, Ezra, Daniel G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334856/
https://www.ncbi.nlm.nih.gov/pubmed/32636936
http://dx.doi.org/10.1186/s13044-020-00086-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334856/
https://www.ncbi.nlm.nih.gov/pubmed/32636936
http://dx.doi.org/10.1186/s13044-020-00086-7

Ejemplares similares